Given the promising outcomes and favorable clinical responses of the anti-CCR4 treatment in the comparative canine trial, we examined whether the CCL17–CCR4 axis is associated with tumor-infiltrating Tregs and prognosis in patients with human prostate cancer. This evidence concerns the gene CCR4 and Familial prostate cancer.